Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1260-1266

  Novello, Silvia ^a   Camps, Carlos ^b   Grossi, Francesco ^c   Mazieres, Julien ^d   Abrey, Lauren ^e   Vernejoux, Jean Marc ^f   Thall, Aron ^g   Patyna, Shem ^g   Usari, Tiziana ^g   Wang, Zhixiao ^h   Chao, Richard C ^g   Scagliotti, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF GENOA   (Italy)

^d SERVICE DE PNEUMOLOGIE   (France)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g PFIZER INC   (United States)

^h Pfizer Ltd   (United States)

Author keywords

Brain metastases; Non small cell lung cancer; Safety; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DECREASED APPETITE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RISK; SUICIDE; THREE DIMENSIONAL IMAGING;

EID: 79959908104     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318219a973     Document Type: Article

References (45)

1. Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: Long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 2002;97:1276-1281. (Pubitemid 35424280)
2. Grossi F, Scolaro T, Tixi L, et al. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol 2001;37:61-67. (Pubitemid 32063318)
3. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-1537.
4. Srivastava G, Rana V, Wallace S, et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol 2009;4:333-337.
5. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207-6219.
6. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study. Cancer Invest 2002;20:293-302. (Pubitemid 34496561)
7. Edelman MJ, Belani CP, Socinski MA, et al. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:110-116.
8. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-3530. (Pubitemid 29517923)
9. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/ cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003;64:28-35. (Pubitemid 35477952)
10. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of nonsmall- cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001;12:59-67. (Pubitemid 32162449)
11. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 2004;15:1042-1047. (Pubitemid 39089780)
12. Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol 2004;2:405-410. (Pubitemid 39419689)
13. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008;10:624-630.
14. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10: 28-35.
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
16. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
17. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 2008;9: 102-105. (Pubitemid 351631921)
18. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
19. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-4280.
20. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-5261.
21. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16:269-278.
22. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656. (Pubitemid 351264362)
23. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol 2009;10:757-763.
24. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a twopart, double-blind, randomized phase II study. J Clin Oncol 2009;27: 2523-2529.
25. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100:443-447.
26. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337. (Pubitemid 36109749)
27. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478.
28. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605. (Pubitemid 36857948)
29. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766. (Pubitemid 38019277)
30. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-1548.
31. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60:4959-4967.
32. Patyna S, Peng J. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 2006;4:21.
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
34. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Eval Health Prof 2005;28:172-191. (Pubitemid 40628906)
35. Medioni J, Cojocarasu O, Belcaceres J-L, et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007;18:1282-1283. (Pubitemid 47244377)
36. Patyna S, Heward JK, Evering W. Non-clinical safety evaluation of sunitinib, a novel multitargeted tyrosine kinase inhibitor. Presented at the 25th Annual Meeting of the Society of Toxicological Pathology, Vancouver, BC, Canada, June 18-22, 2006 (Abstract 42).
37. Otterson GA, O'Connor PG, Lin M, et al. Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo(P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. J Clin Oncol 2009;27(15s Suppl): Abstract e19025.
38. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol 2008;86:243-244. (Pubitemid 350263426)
39. Koutras AK, Krikelis D, Alexandrou N, et al. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 2007;27:4255-4257.
40. Hill KL Jr, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg 2009;111:497-503.
41. Zeng H, Li X, Yao J, et al. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int 2009;83: 482-485.
42. Wuthrick E, Curran W, Werner-Wasik M, et al. A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. J Clin Oncol 2008;26(Suppl):Abstract 2053.
43. Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;117:501-509.
44. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368: 1329-1338. (Pubitemid 44528723)
45. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-3748.